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Editorial on the Research Topic
Immunology of Vitiligo
Disappearance of melanocytes is the pathogenic hallmark of vitiligo. Progressive depigmentation of
the skin has a high negative impact on patients’ quality of life. To date, vitiligo remains a therapeutic
challenge (1).
Several theories have been proposed to explain disease pathogenesis, considering the roles of
increased inflammatory and cytotoxic immune responses, neuropeptides, microvascular anomalies,
intrinsic abnormalities in melanocyte and keratinocyte adhesion, as well as oxidative stress (2). Over
the past decades, clinical, basic, and translational research on patient samples as well as in vitro and
in vivo models have tremendously improved our understanding of the pathophysiology of the
disease and highlighted its complexity. Such progress is of utmost importance to identify
appropriate therapeutic targets and treatments to halt progression of the disease and to induce
repigmentation. “Immunology of vitiligo” is a collection of six review articles and four original
articles focusing on complementary aspects of the immune pathways involved in vitiligo, from a
pathophysiologic to a therapeutic perspective.
Mechanisms leading to the loss of melanocytes include genetic predispositions and
environmental triggers, as well as metabolic and immune alterations (3, 4). Epigenetic
modifications may also be involved in vitiligo pathogenesis, as suggested in the Pu et al. study
that identifies altered methylation levels of key genes involved in oxidation-reduction,
inflammatory, or pigmentation processes in vitiligo melanocyte cell lines. Most of the published
studies focused on the role of the immune response in non-segmental vitiligo (or vitiligo), which
accounts for approximately 90% of clinical forms; segmental vitiligo being less well-studied. In their
review, Speeckaert et al. emphasize the role of autoimmunity in segmental vitiligo, likely involving a
targeted immune response against melanocytes carrying a somatic mutation (5). Indeed, as shown
by Yang et al., transcriptomic analysis of lesional skin of segmental vitiligo versus non-segmental
vitiligo showed similar changes in dysregulated immune pathways.
The innate immune response is important for the initiation of the disease. Jadeja et al. discuss the
role of the endoplasmic reticulum stress-induced unfolded protein response as a bridge between
oxidative stress and the development of autoimmunity in vitiligo. Danger signals (DAMPs and
PAMPs) together with the role of innate immune cells in vitiligo pathogenesis is further reviewed byorg June 2021 | Volume 12 | Article 7110801
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cell immune responses, leading to the loss of melanocytes.
Indeed, CD8+ T cells infiltrating the skin of vitiligo patients
play a direct role in melanocyte disappearance, through their
cytotoxic activity and the release of type 1 cytokines, in particular
IFNg and TNFa (6, 7). More recent studies also described the
role of resident memory T cells expressing the IL-15 receptor,
CXCR3, and NKG2D, and targeting this subset appears to
prevent disease progression, flares, and to maintain
repigmentation after treatment (2, 8). In this context, Plaza-
Rojas and Guevara-Patiño discuss the role of the NKG2D/
NKG2D ligand axis, and Willemsen et al. the relevance of
targeting the PD-1/PD-L1 axis in vitiligo. Disruption of
tolerance is a hallmark of autoimmunity and previous studies
describe dysregulation of regulatory T cell function and/or
number in patients (9, 10). In their original article,
Mukhatayev et al. elegantly investigated the potential of using
CAR Tregs as a therapeutic strategy in a pre-clinical humanized
mouse model prone to develop vitiligo. The importance of using
appropriate in vitro and in vivo pre-clinical models to perform
mechanistic and translational studies is outlined in the Katz and
Harris review. Animal models with spontaneous development ofFrontiers in Immunology | www.frontiersin.org 2vitiligo are not optimal to fully understand the complexity of the
human disease. In their case series, Egbeto et al. described a
similar immune profile between canine and human autoimmune
pigmentary disorders, suggesting that findings in one model
could be relevant to the other.
In conclusion, the prominent role of autoimmunity in vitiligo
pathogenesis is now evident, as exemplified with recent clinical
studies evaluating the efficacy of drugs targeting the immune
response, such as JAK inhibitors (11, 12). Yet prediction of drug
efficacy is important for personalized therapeutic management of
patients. Yang et al. identified biomarkers of innate and adaptive
immune responses associated with favorable response to therapy.
It will be also important to assess whether new therapies induce
durable repigmentation of vitiligo, or whether maintenance
therapies will be required to prevent disease relapse.AUTHOR CONTRIBUTIONS
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